Literature DB >> 8090451

Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors.

A Glacet-Bernard1, A Chabanel, F Lelong, M M Samama, G Coscas.   

Abstract

BACKGROUND: Retinal venous circulation is characterized by the combination of a low flow state and a high vascular resistance, which would make it particularly dependent on blood viscosity. Erythrocyte aggregation is the chief determinant of blood viscosity at low shear rates. Recent studies have demonstrated increased erythrocyte aggregation in many systemic vascular disorders and also in retinal vein occlusion.
METHODS: To assess the possible role of abnormal hemorheologic findings in the pathogenesis of central retinal vein occlusion (CRVO), the authors retrospectively studied erythrocyte aggregation and hematocrit and fibrinogen levels in 33 patients with CRVO and without any known risk factors (diabetes, hypertension, smoking, hyperlipidemia, cardiovascular disease, glaucoma). Erythrocyte aggregation was assessed with a light back-scattering method. Results were compared with those of a group of 33 age- and sex-matched controls.
RESULTS: Eleven (33%) of the 33 patients with CRVO had abnormal hemorheologic findings. Erythrocyte aggregation was highly significantly increased in the CRVO group when compared with the control group (P < 0.0001), as was the hematocrit level (P < 0.05). In addition, the proportion of patients with abnormal blood rheologic tests was greater (50%) in the subgroup of patients who initially had nonischemic CRVO that worsened into an ischemic CRVO during the follow-up.
CONCLUSION: These data suggest that abnormal hemorheologic findings could affect the pathogenesis of CRVO, and perhaps be predictive of an aggravation. The latter hypothesis needs to be confirmed in a larger, prospective study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090451     DOI: 10.1016/s0161-6420(13)31146-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.

Authors:  A Glacet-Bernard; D Kuhn; A K Vine; H Oubraham; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 3.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

4.  Follow up by colour Doppler imaging of 102 patients with retinal vein occlusion over 1 year.

Authors:  S Arséne; B Giraudeau; M-L Le Lez; P J Pisella; L Pourcelot; F Tranquart
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

5.  Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study.

Authors:  Agnès Glacet-Bernard; Marielle Atassi; Christine Fardeau; Jean-Paul Romanet; Matthieu Tonini; John Conrath; Philippe Denis; Martine Mauget-Faÿsse; Gabriel Coscas; Gisèle Soubrane; Eric Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-17       Impact factor: 3.117

6.  Anterior chamber depth and angle-closure glaucoma after central retinal vein occlusion.

Authors:  Shiu-Chen Wu; Yung-Sung Lee; Wei-Chi Wu; Shirley H L Chang
Journal:  BMC Ophthalmol       Date:  2016-05-31       Impact factor: 2.209

7.  Bilateral Central Retinal Vein Occlusion, multiple dental implants and severe glomerulonephtitis - Any connection?

Authors:  Monica Malaescu; Bogdana Tabacaru; Simona Stanca; Tudor Horia Stanca
Journal:  Rom J Ophthalmol       Date:  2019 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.